No, it was discussed on the last CC: Emily Lee: Would

New Post Public Reply Private Reply Replies (0) Message Board
docj Beasley #13888
307
No, it was discussed on the last CC:

Emily Lee: Would you be able to give some color on the diagnostic testing? Are we devising
something there? Do we have any potential partners?
Joe Moscato: Yeah, that is a great question. Dr. Hal Hanes is on, so he can answer that who
runs our subsidiary NuGenerex diagnostics. There are tests right now, Emily,
that the CDC has made up. Those tests have to go to the lab. Obviously, our
technology with our diagnostic company is rapid testing, which can give a
response immediately. This is where it does not go to the lab and you are
waiting 24 to 48 hours to get a result. Hal, maybe you would like to go through
what you have been investigating, as well as what potential we have in creating
a rapid diagnostic handheld kit.
Dr. Hal Hanes: Sure Joe, thanks. That is a great question. If you think about what is happening
right now in China on the ground or in other potential high prevalent areas of
coronavirus infection, people are fearful. They are extremely fearful. You see
condo buildings being shut down in Hong Kong. You see whole cities in China
which have streets that are deserted except for necessities. The coronavirus
infection just basically starts out like a common cold or other infection, which
causes fever and sneezing. It is an upper respiratory virus infection. If you can
diagnose it at an early stage in the disease when people do have these initial
symptoms, you could very likely get them into isolation if they do have the
coronavirus. Make sure they are released if they do not have it. They are not a
danger. They can go home and do what they wish. Right now on incoming
airplanes from China, people are being isolated. You have looked at the news
about cruise ships where there is an outbreak, and the whole cruise ship is stuck
at a dock for two weeks or longer. This is to make sure there is no continual
spread.
Generex Investor Call Feb. 13, 2020
Page 30 of 31
Using Eric’s peptides, we can very likely and almost certainly develop an assay. It
would be an oral fluid assay in which a swab is taken from the throat, nose, or
upper respiratory tract. The virus can be detected directly from that swab on
our proprietary Express 2 platform. This test would take about 10 to 15 minutes
to read. It can be done by minimally trained personnel. They do not have to be
lab techs. They do not have to be nurses or doctors. It can be done in a clinic,
but it can also be used at points of entry by security agents. It is by anybody that
is trained a little bit in running the test. Simply take a swab, put it in the tube,
put the test in the swab of the tube, and it develops. That way people who get
into these high security areas can be screened quickly. By the way, most people
who have these symptoms do not have coronavirus.
There is a lot of overlapping symptomatology like the common cold or flu that
give you the same thing. Right now, if you are in those areas you think you
probably do have the coronavirus. We feel this is going to be a rapid test. It can
be done rapidly. It is cheap to produce once we have the proper peptides. It can
be administered universally practically anywhere. That was a great question
right there. Thanks.
Emily Lee: Is there a timeframe where this can be developed for the test tubes?
Dr. Hal Hanes: Yeah. I can give you an estimate. I certainly do not know. It would require us
taking the peptides that Eric produces and analyze this to make sure they are
proper ones. It is raising antibodies to them in animals. This can be done
relatively quickly. There are lots of animals where it can be done that way. Use
those antibodies as the analytical reagent. In other words, we put them on a
strip. It is like a diabetes strip, except for infectious diseases. We have a lot of
expertise in this. We put them on a strip. We have a control line. We put the
oral fluid after it has been diluted. Let it run up on the strip. The line with the
antibodies to the coronavirus, if there is a coronavirus in that sample, will light
up. The control line will light up. We will be able to say that person does not or
does have coronavirus. I would say probably once the peptides are fully
developed and we can immunize animals with them, there are many companies
that can do this rapidly. We should probably have an assay in three to four
months after those events occur.
Emily Lee: All right. Thank you so much. Are there any interested parties out there? For
example, is the Chinese government aware of this diagnostic test kit that you
guys are?
Dr. Hal Hanes: I think, Joe, you can answer this. I think this is part of the presentation to them
as an aside to the vaccine. Diagnosis goes hand-in-hand together with treatment
or vaccination. You have to have the diagnosis. The vaccination you can use for
everybody. We need to know the diagnosis for people to get treated properly.
Those who have had the virus probably do not need to get diagnosed.
Joe Moscato: Yeah, do not forget too. We are not treatment. We are vaccination.
Generex Investor Call Feb. 13, 2020
Page 31 of 31
Dr. Hal Hanes: Right. Right.
Joe Moscato: Treatment is like a Gilead product. You know? You have corona. You are very,
very sick. You are in a hospital. You have major symptomatic events going on.
Then they give you the Gilead product. Here, we are trying to guard against
severe symptoms at the very least. Guard against severe symptoms. This is all
the way up to full inoculations. That is something that we have discussed with
our Chinese partners. The big interest right now is the vaccine.
Emily Lee: I see. It just seemed like there was such a low supply of test kits. I would think
the test kit should be of great interest too. This is especially recently I read on
the news that some test kits provided to different states or cities are faulty in
the US. I would just think this could be a very huge opportunity.
Joe Moscato: Yeah, we feel the same exact way. I mean, in reality, doing the tests that are
now provided takes time. You have to send them to a lab. The lab has thousands
and thousands of these test kits, I am sure, based upon what is going on out
there. It is going to take time to get those diagnoses. Here, we have a rapid,
ready to go, in-hand test that lets you know five or ten minutes later if that
person is infected. Though we have not made great strides yet in figuring out
how to commercialize that for what is going on right now, the main focus has
been right now the vaccine.
Emily Lee: Okay yeah. Okay great. Thank you so much for your hard work. It sounds
wonderful what you guys are doing. I appreciate your hard work.

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Dickinson Brands Celebrates Witch Hazel Legacy with Event

Updated Category News Views 1

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Continue Reading
AEVEX Faces 48-Hour Deadline for Investor Class Action

Updated Category News Views 43

Clock Ticking on AEVEX Lawsuit Participation Ah, the twists and turns of the stock market! AEVEX Corp. (NYSE: AVEX) finds itself knee-deep in a class action lawsuit, and investors have a mere 48 hours left to make their stand as the lead plaintiff. This legal saga stems from the company's April 2026 IPO and spills into the muddy waters of securities law violations....

Continue Reading
AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Updated Category News Views 2

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Continue Reading
Chicago Scenic Studios’ Equipment Up for Grabs in Auction

Updated Category News Views 3

A Peek into the Sale: What's on the Block? Get that coffee brewing and settle in, because we've got to unpack some interesting stuff happening with Chicago Scenic Studios. This isn't just any Craigslist decampment—Integra Asset Solutions is rolling out an online auction come October 27 that’ll have equipment-savvy investors’ ears perking up like they just snagged a...

Continue Reading
Venue Two Eleven: Historic Charm Meets Modern Events

Updated Category News Views 3

Welcome To Venue Two Eleven: Where History Meets Modernity Alright, folks. Let’s talk about Venue Two Eleven—a new joint in town that’s blending the old with the new in a way that’s got me raising an eyebrow and maybe even sipping my coffee a little slower. Nestled in the Museum of the Oregon Territory, this place is pulling double duty as both a window to the...

Continue Reading
Tomorrowland's Shanghai Return: An Electri-Lifesaver

Updated Category News Views 67

You know, every now and then, it's worth stepping out of the stock frenzy and diving into something as electrifying and far from the trading floor as Tomorrowland's latest Shanghai rendezvous. This ain't just any festival; it's the kind of hype that packs a punch—and frankly, it's a wild ride seeing such a spectacle set up shop in China, and sell out to boot. Partnering...

Continue Reading
Kansai Medical Ushers in New Era of Cancer Research

Updated Category News Views 1

Breaking Ground in Cancer Treatment Trials I've seen some thrilling breakthroughs in my time following the pharmaceutical industry, but what Kansai Medical University and Daiichi Sankyo are doing elevates the game. They're rolling out the first patient dose of DS1025 in Osaka, Japan—a move that marks the onset of a global Phase 1 clinical trial. This is no ordinary...

Continue Reading
Antheia Secures $80M for Critical Medicine Onshoring

Updated Category News Views 41

Antheia's Bold Move to Onshore Medicine Production Folks, when it comes to pharmaceuticals, it's about time someone started serious about keeping things closer to home. Antheia just landed a huge $80 million conditional commitment from the U.S. Department of War's Office of Strategic Capital. The fine print? This isn't just about building business—it's a play to secure...

Continue Reading
Nomada Fund Launches: A Game-Changer in New Media

Updated Category News Views 3

Changing the Investment Game In a world where tech isn't the only kingmaker, distribution is the new play. Welcome the Nomada Fund, a fresh face on the investment scene that's swapping cash for exposure. Forget the traditional media-for-equity model that only old-timers still drool over—these guys are taking it up a notch with their new Distribution for Equity approach,...

Continue Reading
AI-Designed Antivirals: A Brave New World

Updated Category News Views 2

Pushing the Boundaries with AI in Drug Discovery It seems some smart folks over in South Korea are giving the pharma game a fresh twist, pitting artificial intelligence against viral invaders in a newfangled brawl. Professors from Korea University have managed to blend AI's computing prowess with good ol' lab doggedness to sniff out potential antiviral compounds. The...

Continue Reading

Top 5 Most Recently Viewed Articles

Maya Harris-Cameron Joins The Reserve Component as Director

Updated Category News Views 205

Welcome Maya Harris-Cameron to The Reserve Component In an exciting development, The Reserve Component (TRC), a distinguished government relations firm known for its strategic lobbying prowess, has welcomed Maya Harris-Cameron as its new Director. With her extensive experience and impressive background, she is poised to make a significant impact. Professional Background...

Continue Reading
Helient Technologies Appoints Andrew Goetz as Director of Partnerships

Updated Category News Views 314

Helient Technologies Announces New Leadership Appointment Helient Technologies is excited to share significant news regarding its leadership team. The company has appointed Andrew Goetz, a highly respected figure in the telecommunications industry, as the new Director of Channel Partnerships. This strategic addition is aligned with Helient's vision to strengthen its...

Continue Reading
Innovative Water Jug Attachment Streamlines Dispensing Process

Updated Category News Views 81

Introducing a Game-Changing Water Jug Attachment There's a revolutionary new product designed to enhance the way we handle water jugs. An inventive mind has developed a unique attachment specifically for multi-gallon jugs, making water dispensing a breeze. This innovation stems from the desire to provide an easier solution for families and businesses alike, ensuring that...

Continue Reading
Investors Gain Opportunities in Freeport-McMoRan Securities Fraud Case

Updated Category News Views 208

Introduction to Freeport-McMoRan Securities Lawsuit Investors in Freeport-McMoRan Inc. (NYSE: FCX) are currently presented with an opportunity to participate in a significant class action lawsuit against the company. This legal action is being spearheaded by a reputable law firm that specializes in investor rights, focusing on allegations of securities fraud that occurred...

Continue Reading
Revolutionizing Gaming: Slips Launches AI Betting Markets

Updated Category News Views 219

Revolutionizing Gaming with AI-Generated Prediction Markets Slips, an innovative social peer-to-peer betting app, is transforming the landscape of real-money gaming with the introduction of its AI-Generated Prediction Markets. This groundbreaking feature enables players to wager on a wide array of topics, from the latest sports events to political elections and beyond....

Continue Reading